Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 153

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 153
---
ivat)7,852 4,488 13,240 6,383 In-process research and development10,000 — 10,000 — Other research and platform programs5,394 7,270 8,838 10,955 Total direct research and development expenses53,055 39,726 83,208 71,342 Compensation and related expenses27,594 27,476 60,584 55,110 Facilities and IT related expenses & other11,291 10,199 20,891 19,569 Total indirect research and development expenses38,885 37,675 81,475 74,679 Total research and development expense$91,940 $77,401 $164,683 $146,021 

24

Total Research and Development Expenses - Three Months Ended June 30, 2025 vs. Three Months Ended June 30, 2024 – The increase in total research and development expenses of $14.5 million for the three months ended June 30, 2025 compared to the three months ended June 30, 2024 was primarily due to a $13.3 million increase in our direct expenses. The increase in direct expenses was primarily due to in-process research and development as a result of the $10.0 million milestone payment associated with the agreement with Alnylam discussed above under Overview.

Total Research and Development Expenses - Six Months Ended June 30, 2025 vs. Six Months Ended June 30, 2024 – The increase in total research and development expenses of $18.7 million for the six months ended June 30, 2025 compared to the six months ended June 30, 2024 was due to a $11.9 million increase in our direct expenses and a $6.8 million increase in our indirect expenses. The increase in direct expenses was primarily due to in-process research and development as a result of the $10.0 million milestone payment associated with the agreement with Alnylam discussed above under Overview, and an increase in tebapivat costs due to increased costs associated with clinical trials of tebapivat in patients with SCD and LR MDS. These increases were partially offset by a decrease in PYRUKYND® costs due to lower process development expenses, lower costs associated with the phase 3 ACTIVATE-Kids and ACTIVATE-KidsT trials, and lower costs associated